



April 14, 2020

Nira Pollock, M.D., Ph.D  
Associate Medical Director, Infectious Diseases Diagnostic Laboratory (IDDL)  
Boston Children's Hospital  
300 Longwood Avenue, Farley Building, 8<sup>th</sup> Floor, Room FA828  
Boston, MA 02115

Re: EUA200084  
Trade/Device Name: Childrens-Altona-SARS-CoV-2 Assay  
Laboratory: Infectious Diseases Diagnostics Laboratory (IDDL), Boston Children's Hospital  
Dated: March 27, 2020  
Received: March 27, 2020

Dear Dr. Pollock:

This letter is in response to your request that the Food and Drug Administration (FDA) add your test as an authorized test to the March 31, 2020 Emergency Use Authorization (EUA), pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. §360bbb-3). We have reviewed the EUA submission package and determined that your test meets the criteria for issuance under section 564(c) of the Act because your test is eligible for authorization under the March 31, 2020 EUA for Molecular-based Laboratory Developed Tests for Detection of Nucleic Acid from SARS-CoV-2 (Molecular LDT COVID-19 Authorized Test). As such, your test is hereby added to Appendix A<sup>1</sup> as an authorized test.

Having concluded that the criteria for issuance of this authorization under Section 564(c) of the Act are met, I am adding this test to Appendix A as an authorized test, as described in the Scope of Authorization (Section II) and pursuant to the Conditions of Authorization (Section IV) of the attached letter of authorization<sup>2</sup> for use by the authorized laboratory to detect SARS-CoV-2 in specimens collected from individuals suspected of COVID-19 by their healthcare provider. Accordingly, in addition to this letter, you will receive copies of the FDA Letter of Authorization and the authorized Healthcare Provider and Patient Fact Sheets that must be used in conjunction with your authorized test pursuant to the Conditions of Authorization (Section IV) of the Letter of Authorization.

Sincerely yours,

---

Uwe Scherf, M.Sc., Ph.D.  
Director, Division of Microbiology Devices  
OHT7: Office of In Vitro Diagnostics and Radiological Health  
Office of Product Evaluation and Quality  
Center for Devices and Radiological Health

---

<sup>1</sup> Appendix A is available at, <https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations>.

<sup>2</sup> The Letter of Authorization is available at, <https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations>.